A phase 1 evaluation of [18F]MK-6240 as a potential PET radioligand for imaging tau protein in the brain of cognitively normal elderly Japanese participants, Japanese patients with mild cognitive impairment and probable mild to moderate Alzheimer's disease
Latest Information Update: 20 Dec 2021
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Cerveau Technologies; Cmic
- 20 Dec 2021 New trial record